Screening analysis software adds safety and toxicity analysis for the FLIPR Tetra high throughput cellular screening system
Molecular Devices has launched the ScreenWorks Peak Pro Analysis Module for the FLIPR Tetra System.
The software offers the ability to analyse multi-peak calcium oscillation responses of cells, and in particular beating cardiomyocytes, to characterise cardiotoxic and cardioactive compounds during a high throughput screen.
The ScreenWorks Peak Pro analysis is able to measure cardiomyocyte beat rate, as well as temporal characteristics of peaks including rise, decrease, and amplitude.
According to the company, these features are important for researchers to better understand in vitro cardiomyocyte function and the impact of toxic compounds that induce cardiac abnormalities.
With ScreenWorks Peak Pro, the FLIPR Tetra System offers the potential to perform safety testing, such as cardiotoxicity, early in the drug discovery pipeline, thereby allowing researchers to fail toxic compounds sooner.
The system also allows users to estimate efficacy and dosing of a drug candidate prior to progression into clinical studies.
In addition, it enables increased throughput and cuts time by delivering advanced and simplified data analysis for multiple parameters.
The ScreenWorks Peak Pro analysis module, when used with the FLIPR Tetra System and the FLIPR Calcium 5 Assay Kit, can provide a screening method for changes in intracellular calcium associated with cardiomyocyte contractions.
Integrated fluidics enables simultaneous evaluation of up to 1536 wells in less than two minutes, and therefore gives users the ability to determine the immediate impact of compounds on cells.
This method may be used with both primary and stem-cell derived, human and mouse cardiomyocytes.
